Efficacy of intrathecal chemotherapy in patients with central nervous system involvement of hematological malignancies: a retrospective analysis
Central nervous system (CNS) involvement, especially involvement of the cerebrospinal fluid (CSF), is common in several haematological malignancies. Intrathecal (IT) chemotherapy can be used to manage CSF involvement.
Here we evaluated the effectiveness of IT chemotherapy among 80 patients with haematological malignancies and CSF localization who were treated with IT chemotherapy from 2001 to 2012.
The majority of patients was diagnosed with diffuse large B-cell lymphoma (26%) or acute lymphoblastic leukaemia/lymphoblastic lymphoma (19%). After first-line IT chemotherapy, which mainly consisted of methotrexate (MTX) and corticosteroids, CSF complete response (CSF CR) was achieved in 76% of patients. 91% reached CSF CR when including second-line IT-chemotherapy. Clinical response was documented in 75%. Although most patients were additionally treated with systemic chemotherapy, response rate did not differ between patients treated with CNS-penetrating and CNS-non-penetrating drugs. CNS progression/relapse occurred in 40% of patients with median progression-free survival of 12.2 months. The median overall survival was 18.3 months; 55% of the patients died during follow-up.
Our analysis shows a high response rate after first-line IT chemotherapy, but also a relatively high progression/relapse percentage.
KeywordsIntrathecal chemotherapy Hematological malignancies Methotrexate Cerebrospinal fluid
Compliance with ethical standards
Conflict of interest
All authors report no conflict of interest.
- 2.O’Neill BP (2003) Neurologic complications of Hodgkins’s disease and the non-Hodgkin’s lymphomas. In: Schiff D, Wen PY (eds) Cancer neurology in clinical practice, 1st edn. Humana Press, Totowa, pp 371–384Google Scholar
- 3.Pui CH, Thiel E (2009) Central nervous system disease in hematologic malignancies: historical perspective and practical applications. Semin Oncol 36(4 Suppl 2):S2–S16Google Scholar
- 5.Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M et al (2011) First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol 29(20):2766–2772CrossRefPubMedGoogle Scholar
- 7.Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M et al (2007) Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Ann Oncol 18(1):149–157CrossRefPubMedGoogle Scholar
- 8.Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, Glass B, Scott DW, Gascoyne RD, Connors JM, Ziepert M, Pfreundschuh M, Loeffler M, Savage KJ (2016) CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 34(26):3150–3156CrossRefPubMedGoogle Scholar
- 14.Hegde U, Filie A, Little RF, Janik JE, Grant N, Steinberg SM et al (2005) High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 105(2):496–502CrossRefPubMedGoogle Scholar
- 17.Parasole R, Petruzziello F, Messina C, Barisone E, Pession A, Locatelli F et al (2015) Toxicity and efficacy of intrathecal liposomal cytarabine in children with leukemia/lymphoma relapsing in the central nervous system: a retrospective multicenter study. Leuk Lymphoma 56(3):650–655CrossRefPubMedGoogle Scholar
- 19.Abramson JS, Hellmann M, Barnes JA, Hammerman P, Toomey C, Takvorian T et al (2010) Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer 15(18):4283–4290 116(CrossRefGoogle Scholar